Enhanced Prediction Model for Major Adverse Events Following Acute Myocardial Infarction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jun Jiang, MD
- Phone Number: +86 15657125311
- Email: 21918219@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years old
- Presented with myocardial infarction, including NSTEMI and STEMI
- Undergoing successful percutaneous coronary intervention.
Exclusion Criteria:
- Subjects who decline protocol-mandated follow-up or withhold informed consent.
- Individuals whose expected survival is < 1 year.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
MI group
Patients who present with myocardial infarction and undergo successful percutaneous coronary intervention will be eligible for enrollment.
|
Percutaneous coronary intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrent myocardial infarction or cardiac death
Time Frame: At 24-month Follow-up
|
Patients received recurrent myocardial infarction or cardiac death
|
At 24-month Follow-up
|
|
Diagnostic performance
Time Frame: At 24-month follow-up
|
Diagnostic performance of the AI-driven multimodal predictive model: area under the receiver-operating characteristic curve (AUC), sensitivity, specificity, overall accuracy, positive predictive value (PPV), and negative predictive value (NPV).
|
At 24-month follow-up
|
|
MACE at 24 months
Time Frame: At 24-month follow-up
|
Major adverse cardiovascular events, defined as a compisite of cardiac death, myocardial infarction, target vessel revascularization.
|
At 24-month follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MACE at 60 months
Time Frame: At 60-month follow-up
|
Major adverse cardiovascular events, defined as a compisite of cardiac death, myocardial infarction, target vessel revascularization.
|
At 60-month follow-up
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MACE according to pre-specified subgroups
Time Frame: At 24- and 60-month follow-up
|
MACE stratified by sex, diabetes status, and chronic kidney disease (CKD) status.
|
At 24- and 60-month follow-up
|
|
MACE according to physiological status
Time Frame: At 24- and 60-month follow-up
|
MACE prediction integrating physiological metrics-angiographic FFR, IMR, MRR, and CFR-of the culprit and non-culprit coronary arteries.
|
At 24- and 60-month follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Infarction
- Necrosis
- Myocardial Ischemia
- Ischemia
- Pathological Conditions, Signs and Symptoms
- Myocardial Infarction
- Surgical Procedures, Operative
- Endovascular Procedures
- Vascular Surgical Procedures
- Cardiovascular Surgical Procedures
- Minimally Invasive Surgical Procedures
- Percutaneous Coronary Intervention
Other Study ID Numbers
Other Study ID Numbers
- 2025-1224
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.